Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis

Inclusion Criteria: * Patients must have proven, probable or possible invasive fungal disease caused by Aspergillus species or other filamentous fungi * Female patients must be non-lactating and at no risk for pregnancy Exclusion Criteria: * Patients with invasive fungal infections other than Aspergillus species or other filamentous fungi * Evidence of hepatic dysfunction at Baseline or moderate to severe renal dysfunction * Patients with chronic aspergillosis, or aspergilloma or allergic bronchopulmonary aspergillosis * Patients who have received more than 4 days of systemic antifungal therapy other than fluconazole within the 7 days prior to the first administration of study medication * Patients previously enrolled in a Phase III study with isavuconazole * Patients with a body weight \</= 40 kg